P2RX7 and cancer: Interestingly, when CT26 CRC cells were administered in BALB/c mice subcutaneously, only co-administration of both P2X7 and A2A antagonist was effective in reducing cancer growth (Fig. 6A, B) and the levels of IL-17 (Fig. 6C).